AnTolRx, Inc.

BOSTON, MA · Founded 2015 · Biotech · Private

novel patented therapies for autoimmune diseases

Claim this profile

Follows are private to you and power your alerts

Updated · antolrx.com

Sector
Biotech
Headquarters
BOSTON, MA
Founded
2015
Latest Form D
$1M, Jul 2016
Total capital
$1M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$1M
1 Form D · last Jul 2016
124 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
3 pending · first 2024
Rank in peer group#481 of 1449

Capital timeline

2016FEDERAL ↑EQUITY ↓Cumulative $1M1st Form D$1M
2016FEDERAL ↑EQUITY ↓Cumulative $1M1st Form D$1M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$1M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#481 · top 33%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Francisco QuintanaDirectorNamed in SEC Form D filings
  • Mark CarthyExecutive Officer, DirectorNamed in SEC Form D filings
  • Satish JindalDirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 4
  • GrantedTolerogenic Liposomes And Methods Of Use ThereofUSPTOUS 12,178,908
  • PendingImmune Tolerization Agents And PotentiatorsUSPTOApplication 17626540
  • PendingImmune Tolerization Agents And PotentiatorsUSPTOApplication PCTUS2020042385
Show all 4 patent records
  • Tolerogenic Liposomes And Methods Of Use ThereofDec 31, 2024 · US 12,178,908Granted
  • Immune Tolerization Agents And PotentiatorsDec 8, 2022 · Application 17626540Pending
  • Immune Tolerization Agents And PotentiatorsApplication PCTUS2020042385Pending
  • Tolerogenic Liposomes And Methods Of Use ThereofApplication PCTUS2019019609Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .